A previous study indicated that treatment with the GLP-1 agonist liraglutide (subcutaneously at a dose gradually titrated from 0.6 to 3 mg) in bipolar and mood disorder depression patients could result in an improvement in cognitive function and an alleviation of depressive pathological symptoms ( Considering this evidence, increasing neurogenesis in the brain through the GLP-1 pathway may provide a novel approach for improving depressive-like behavior in patients with depression
Shannen Zitz is the Associate Style & Reviews Editor at Women's Health , where she covers all-things sneakers and activewear
10.1038/s42255-020-0171-3 126 Sanchez-GarridoM
Access this article Similar content being viewed by others Data availability All data supporting the findings of this study are available within the review article
Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW
While Blunts version of "Piece of My Heart" gave us goosebumps, this was Hathaways show from start to finish